Nuvectis Pharma (NVCT) Cash from Financing Activities (2021 - 2026)

Nuvectis Pharma has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $7000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $7000.0, down 99.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (down 39.4% YoY), and the FY2025 annual result was $29.1 million, up 149.79% from the prior year.
• Cash from Financing Activities came in at $7000.0 for Q1 2026 at Nuvectis Pharma, down from $166000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $15.5 million in Q1 2025 to a low of -$578000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $1.5 million (2024), against an average of $4.9 million.
• Across the five-year window, Cash from Financing Activities surged 2386.33% in 2023 and sank 99.95% in 2026, its largest moves.
• Nuvectis Pharma's Cash from Financing Activities stood at -$131000.0 in 2022, then soared by 800.0% to $917000.0 in 2023, then jumped by 317.56% to $3.8 million in 2024, then sank by 95.66% to $166000.0 in 2025, then tumbled by 95.78% to $7000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $7000.0 (Q1 2026), $166000.0 (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.